The New York-based company previously offered the opportunity for investors to exercise the Series W warrants at a discounted price of $2.00 per share. As of Feb. 8, Pavmed said 34,345 Series W warrants had been tendered for exercise and the company had raised $68,690 in gross cash proceeds.
Each of Pavmed’s outstanding Series W warrants can be exercised for one share of common stock at an exercise price of $5.00 per share until Jan. 29, 2022, while each Z warrant can be exercised for one share of common stock at $3.00 apiece until April 30, 2024.
Pavmed noted that if all W warrants are exchanged as part of its latest offer, the company’s common stock will be cut by 5,283,992 shares.
Pavmed also raised $3.9 million in public offering at the end of last month, saying that it planned to use the funds for working capital and general corporate purposes.
The company sold 2.4 million shares of its common stock at $1.80 apiece in the offering, which also included a 45-day option for underwriters to buy an additional 362,292 shares of common stock to cover over-allotments.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.